for SmPC and package leaflet PCWP/HCP WG Joint meeting 24 September - - PowerPoint PPT Presentation

for smpc and package leaflet
SMART_READER_LITE
LIVE PREVIEW

for SmPC and package leaflet PCWP/HCP WG Joint meeting 24 September - - PowerPoint PPT Presentation

Additional monitoring proposals on the black symbol for SmPC and package leaflet PCWP/HCP WG Joint meeting 24 September 2012 Ana Sempere Product Information Quality Section/Medical Information Sector An agency of the European Union


slide-1
SLIDE 1

An agency of the European Union

Additional monitoring – proposals on the black symbol for SmPC and package leaflet

PCWP/HCP WG Joint meeting 24 September 2012

Ana Sempere Product Information Quality Section/Medical Information Sector

slide-2
SLIDE 2

Contents

  • Legal basis
  • Impact of the new legislation in the product information
  • Identification of the black symbol
  • QRD proposal
  • Summary of the feedback received during consultation (plus examples)
  • Recommendation of the Pharmacovigilance Risk Assessment

Committee (PRAC)

  • What is expected from PRAC?
  • Proposed timelines
  • Patients, consumers and HCP’s views

1

slide-3
SLIDE 3

2

Legal basis Black symbol and additional monitoring

  • For medicinal products for human use subject to additional

monitoring:

– The summary of product characteristics and the package leaflet shall include the statement “This medicinal product is subject to additional monitoring”. That statement shall be preceded by a black symbol which shall be selected by the Commission following a recommendation of the Pharmacovigilance Risk Assessment Committee by 2 January 2012*, and shall be followed by an appropriate standardised explanatory sentence (Art. 11 and 59 of Directive 2001/83/EC and Art. 23(5) of Regulation (EC) No 726/2004).

*Proposal to amend the date to 2 July 2013.

slide-4
SLIDE 4

Impact of the new legislation in the product information

  • The Quality Review of Documents (QRD) group has worked on

draft proposals to be implemented in the product information covering the following aspects:

  • To identify a black symbol

 To assist PRAC when drafting the recommendation on the black symbol for the EC.

  • To specify the location of the symbol and the new standardised

statements within the QRD human product information template.

  • To define the wording for the new standardised statements.

 Additional monitoring.  Encouragement of the reporting of adverse reactions.

3

slide-5
SLIDE 5

Identification of the black symbol QRD proposal

  • The QRD group agreed to propose the inverted black

triangle (▼), as the preferred choice.

  • Symbol already in use in two Member States (Belgium and United Kingdom).
  • No clash with other symbols already established.
  • Measurements and design already set up.
  • As an alternative proposal, the development of a symbol

resembling a magnifying glass was considered by the QRD group to be the second best option.

  • Design needs to be agreed and cost involved.

4

slide-6
SLIDE 6

Identification of the black symbol Summary feedback consultation

  • Inverted triangle

5

Pros Cons  Abstract symbol (not linked to any meaning/connotation) - less likely to cause confusion or alarm to patients.  ‘Not self-explanatory’, it does not suggest any ‘monitoring action’, not ‘eye catching’ and ‘not able to convey the message of additional monitoring’.  Solid representation and easy to reproduce in a consistent manner.  Triangular shape used to identify other activities at national level (e.g. warnings).  Symbol is already in use in two Member States for similar PhV activities.  To develop a brand new symbol only linked to the concept of additional monitoring.  No clash with other symbols already established for pharmaceuticals.  Similar symbols have been previously used in other (non-medical) contexts.  Measurements/design already set up.

slide-7
SLIDE 7

Identification of the black symbol Examples implementation – inverted triangle

  • Examples of current electronic implementation of the inverted

triangle in UK and Belgium:

  • Electronic Medicines Compedium (eMC)
  • Centre Belge d’information pharmacothérapeutique (CBIP)

6

slide-8
SLIDE 8

Identification of the black symbol Summary feedback consultation

  • Magnifying glass

7

Pros Cons  More visual and meaningful symbol to convey the ‘additional monitoring’ idea and support the ‘explanatory sentence’.  Design needs to be agreed, involving a cost.  Used to identify the search tool on websites.  Difficult to recognise by visually impaired patients: less black and less visible upon first glance.  Difficult to reproduce in a consistent manner from a technical viewpoint  The specific measurements may require more space than the inverted triangle.  In the UK, the magnifying glass is used to request leaflets with larger text (symbol user tested for such purpose).

slide-9
SLIDE 9

Identification of the black symbol Examples current use of the magnifying glass

  • Search tool on websites:
  • To request leaflets with larger text (UK):

8

slide-10
SLIDE 10

Identification of the black symbol Examples implementation – magnifying glass

  • Examples implementation of a magnifying glass in leaflets:

9

slide-11
SLIDE 11

Identification of the black symbol Summary feedback consultation

  • Additional comments provided during the consultation:
  • Communication

 Awareness campaign to promote the recognition of the symbol  Education is crucial to ensure that the concept is well understood.

  • User testing

 The short-listed symbols need to be tested with members of the public.

10

slide-12
SLIDE 12

PRAC recommendation What is the EC expecting from PRAC?

  • EC expects the recommendation of the PRAC by the end of

2012.

  • EC wishes to receive a concrete and mature proposal for the

black symbol from the PRAC.

  • Concrete symbol and size (not a concept to be developed).

11

slide-13
SLIDE 13

PRAC recommendation Proposed timelines

  • PRAC September 2012
  • Introduction of the two preferred options for the black symbol proposed by

the QRD group and feedback from the consultations on the proposal.

  • PRAC October 2012
  • Presentation of PCWP/HCP WG views.
  • Further discussion and agreement on the concept regarding the black

symbol and on the specifications (shape, form, design…).

  • PRAC November-December 2012
  • To finalise the PRAC recommendation and provide it to the Commission for

the final selection.

12

slide-14
SLIDE 14

PRAC recommendation Patients, consumers and HCP’s views

  • It is essential to hear the patients, consumers and healthcare

professionals’ voice regarding the black symbol prior to finalising the PRAC recommendation.

  • A representative from the PCWP and HCP WG will be invited to

the PRAC meeting (1-3 October 2012) to present the views on the two proposals for the black symbol.

13

slide-15
SLIDE 15

Thank you!

14